Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anal canal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Anal canal. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-010976-94 Sponsor Protocol Number: gi0901 Start Date*: 2009-07-16
    Sponsor Name:herlev hospital
    Full Title: behandling af patienter med avanceret rectumcancer med capecitabin og oxaliplatin før under og efter kurativt intenderet strålebehandling, samt tillæg af cetuximab til patienter der er K-RAS vild-type
    Medical condition: we will give capecitabine and oxaliplatin togehter with radiation to patient with rectum cancer T3 and T4. We will add cetuximab to patients who are K-RAS wild-type
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002124 Anal canal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-007029-38 Sponsor Protocol Number: ACCORD 16 / 0708 Start Date*: 2008-10-03
    Sponsor Name:FNCLCC
    Full Title: Essai de phase II multicentrique non randomisée étudiant l’impact de l’association radiochimiothérapie (65 Gy + cisplatine + 5FU) au cetuximab chez les patients présentant un cancer anal localement...
    Medical condition: Cancers épidermoïdes du canal anal localement avancé
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002124 Anal canal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005887-24 Sponsor Protocol Number: GEMCAD-2103//MO44170 Start Date*: 2022-11-25
    Sponsor Name:Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD)
    Full Title: Phase II study of Atezolizumab plus Tiraglolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal
    Medical condition: Locallized squamous cell carcinoma of the anal canal in the first-line setting.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002141 Anal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003005-25 Sponsor Protocol Number: RADIANCE Start Date*: 2019-12-17
    Sponsor Name:University Hospital Frankfurt, Goethe University
    Full Title: Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal Cancer Study Group
    Medical condition: anal cancer (UICC-Stage IIB-IIIC, incl. T2>4cm Nany )
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002136 Anal cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002137 Anal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001581-32 Sponsor Protocol Number: 06/0171 Start Date*: 2008-01-22
    Sponsor Name:Joint UCLH & UCL Biomedical Research Unit
    Full Title: Phase I trial of photodynamic therapy using systemic 5-aminolaevulinic acid for the treatment of grade 3 anal intraepithelial neoplasia.
    Medical condition: Grade 3 anal intraepithelial neoplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000948-18 Sponsor Protocol Number: VICORYX Start Date*: 2011-08-25
    Sponsor Name:Oryx GmbH & Co. KG
    Full Title: Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers
    Medical condition: advanced HPV- and p16INK4a-positive cervical, vulvar, vaginal, penile, anal or head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008230 Cervix neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002125 Anal canal neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026339 Malignant neoplasm of penis, part unspecified LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046896 Vaginal neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047750 Vulval neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003351-65 Sponsor Protocol Number: RDD110 Start Date*: 2016-03-16
    Sponsor Name:RDD Pharma Ltd.
    Full Title: The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients with Anal Fissure
    Medical condition: Anal Fissure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000826-24 Sponsor Protocol Number: INCMGA0012-303 Start Date*: 2020-10-29
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carc...
    Medical condition: Male and female participants at least 18 years of age who have inoperable locally recurrent or metastatic Squamous Carcinoma of the Anal Canal (SCAC) not previously treated with systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002127 Anal canal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004749-33 Sponsor Protocol Number: 1381-0011 Start Date*: 2020-06-22
    Sponsor Name:Boehringer Ingelheim Norway KS
    Full Title: An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal
    Medical condition: metastatic squamous cell carcinoma of the anal canal
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055096 Anal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) FI (Prematurely Ended) SE (Prematurely Ended) PT (Prematurely Ended) DE (Completed) LV (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003767-39 Sponsor Protocol Number: 955/08 Start Date*: 2008-09-14
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Concomitant radiochemotherapy with Tegafur and Mitomycin in locally advanced anal canal cancer: Dose Escalation Study.
    Medical condition: locally advanced squamous anal canal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041840 Squamous cell carcinoma of the anus stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018430-48 Sponsor Protocol Number: GEMCAD-09-02 Start Date*: 2010-05-20
    Sponsor Name:Grupo Español Multidisciplinar en cáncer Digestivo-GEMCAD
    Full Title: Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas
    Medical condition: Tratamiento de primera línea para pacientes con cáncer de células escamosas del canal anal locorregional
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003185-27 Sponsor Protocol Number: C17-02 Start Date*: 2018-04-18
    Sponsor Name:GERCOR
    Full Title: A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squa...
    Medical condition: Metastatic or unresectable locally advanced squamous anal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002141 Anal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002070-51 Sponsor Protocol Number: INCMGA0012-202 Start Date*: 2019-07-10
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM 202)
    Medical condition: Squamous Carcinoma of the Anal Canal
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002127 Anal canal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002563-22 Sponsor Protocol Number: 2020/538 Start Date*: 2021-09-13
    Sponsor Name:CHU de Besançon
    Full Title: Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study
    Medical condition: metastatic anal canal cancer
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006046-40 Sponsor Protocol Number: 2020/567 Start Date*: 2021-07-02
    Sponsor Name:CHU de Besançon
    Full Title: Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by hypofractionated radiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study.
    Medical condition: cancer du canal anal de stade III
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000881-39 Sponsor Protocol Number: P/2019/418 Start Date*: 2019-12-10
    Sponsor Name:CHU de Besançon
    Full Title: A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers
    Medical condition: cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002811-33 Sponsor Protocol Number: LAINCO1107 Start Date*: 2017-12-11
    Sponsor Name:LAINCO S.A
    Full Title: Unilateral, open and randomized phase IV study of 2 groups to assess the degree of comfort with simple Emuliquen® in patients undergoing proctological surgery
    Medical condition: Surgery proctological
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016398 10042759 Symptoms involving digestive system LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003532-32 Sponsor Protocol Number: LX1606.1-204-UC Start Date*: 2011-12-19
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Prelimi...
    Medical condition: Acute mild to moderate ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004211-31 Sponsor Protocol Number: CCR3894 Start Date*: 2014-08-20
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer
    Medical condition: Adverse effects of radiotherapy for pelvic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007412-15 Sponsor Protocol Number: CSET 2008/1443 Start Date*: 2009-01-26
    Sponsor Name:Institut Gustave Roussy
    Full Title: Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine ...
    Medical condition: Tumeur pelvienne localement évoluée d’origine gynécologique ou digestive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048936 Pelvic tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 17:12:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA